InvestorsHub Logo
Followers 21
Posts 1331
Boards Moderated 1
Alias Born 07/02/2013

Re: None

Wednesday, 07/17/2013 4:46:39 AM

Wednesday, July 17, 2013 4:46:39 AM

Post# of 1570
JMP Securities Healthcare Conf updates

Tirasemtiv is a first generation fast skeletal troponin activator Cytokinetics has worldwide rights to this compound, CYTK developing it for the potential treatment of ALS in a Phase IIb study called BENEFIT-ALS.


read here
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYTK News